Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 21, 2026Cancer CellOpen Access

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study

View Full Paper
Ask AI
Bookmark
Share

Authors

DPDavid PlanchardNCNathalie CozicMMMaria Fernanda Mosele

Discussion

Loading...

Member takes

Overview

Phase II study shows treatment response and biomarker insights in advanced lung cancer, indicating future precision medicine approaches.

Key Points

  • To evaluate the efficacy and safety of datopotamab deruxtecan, along with the identification of predictive biomarkers in advanced non-small cell lung cancer.
  • Conducted a multicenter, phase II trial with 100 pretreated patients.
  • Administered the TROP2-directed ADC datopotamab deruxtecan.
  • Performed longitudinal tumor analyses to assess treatment response and resistance mechanisms.
  • Reported an objective response rate of 26.0%.
  • Observed a median progression-free survival of 3.6 months, particularly in non-squamous tumors.
  • Identified resistance correlations with TROP2 staining and DNA repair pathway activation.

Cite This Study

Planchard et al. (2026) studied this question.

synapsesocial.com/papers/69e7132bcb99343efc98ceb5https://doi.org/10.1016/j.ccell.2026.03.017
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.2024 · 24 citations
  2. 2Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer2026
  3. 3TROPION-Lung01 Results Indicate PFS Benefit With Datopotamab Deruxtecan Over Docetaxel in Previously Treated Nonsquamous NSCLC. A critique and question2024
  4. 4Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung012024 · 3 citations
  5. 5Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.2024 · 9 citations